close

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly; Nasal Exenatide, a nasal spray formulation of exenatide for diabetes; Pramlintide and PYY 3-36 for the treatment of obesity; Leptin for the treatment of obesity and lipodystrophy; Pramlintide-Metreleptin combination product candidate for overweight or obese subjects; and second generation Amylinomimetic for weight loss. It sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers. The company has collaboration agreements with Eli Lilly and Company, as well as with Alkermes, Inc. to develop exenatide once weekly for diabetes; a joint research collaboration agreement with BioSeek, Inc. for discovery and development of novel peptide therapeutics for inflammatory conditions; and a joint research collaboration agreement with Xenome, Ltd. for discovery and development of novel peptide hormones for a range of metabolic and musculoskeletal diseases. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	15.68
Volume	(mio) 1.44
Volume Avg	(mio) 3.73
52 Week High	18.45
52 Week Low	8.03
PE	N/A
PE (group average)	39
EPS Year	-3.73
EPS change Q/Q	-100%
EPS change Q/Q Yr ago	-3.7%
EPS change Q/Q next Q est	-29.73%
EPS change Y/Y	-19.05%
REV change Q/Q	-12.34%
REV change Q/Q Yr ago	-12.29%
EPS next Q est	-0.37
EPS next Y est	-1.01
Divident Annual	0.00
Dividend Yield	0%